Sanofi (SNY) to Release Quarterly Earnings on Thursday

Sanofi (NASDAQ:SNY) will likely be releasing its Q4 2025 results before the market opens on Thursday, January 29th. Analysts expect Sanofi to post earnings of $0.83 per share and revenue of $11.1756 billion for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, January 29, 2026 at 8:30 AM ET.

Sanofi (NASDAQ:SNY) last issued its earnings results on Friday, October 24th. The company reported $2.91 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $1.31. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The business had revenue of $15.46 billion for the quarter, compared to the consensus estimate of $12.62 billion. During the same period in the previous year, the company earned $2.25 earnings per share. The firm’s revenue for the quarter was down 7.5% on a year-over-year basis. On average, analysts expect Sanofi to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Sanofi Stock Performance

NASDAQ SNY opened at $46.18 on Thursday. The firm has a market capitalization of $112.63 billion, a P/E ratio of 10.82, a price-to-earnings-growth ratio of 1.33 and a beta of 0.45. The company has a current ratio of 1.06, a quick ratio of 0.30 and a debt-to-equity ratio of 0.16. The firm’s fifty day moving average price is $48.68 and its two-hundred day moving average price is $48.78. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12.

Institutional Trading of Sanofi

Several institutional investors have recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in Sanofi by 52.6% in the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after buying an additional 1,869 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Sanofi by 107.2% in the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock valued at $1,693,000 after acquiring an additional 15,791 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Sanofi by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock valued at $2,732,000 after acquiring an additional 752 shares in the last quarter. Sivia Capital Partners LLC increased its position in Sanofi by 5.4% during the second quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock worth $326,000 after acquiring an additional 347 shares during the period. Finally, EverSource Wealth Advisors LLC increased its position in Sanofi by 36.1% during the second quarter. EverSource Wealth Advisors LLC now owns 3,301 shares of the company’s stock worth $159,000 after acquiring an additional 875 shares during the period. 14.03% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

SNY has been the topic of a number of research analyst reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a research note on Monday, December 29th. Barclays downgraded Sanofi from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 6th. TD Cowen reissued a “hold” rating on shares of Sanofi in a report on Tuesday, December 30th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a report on Friday, January 16th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, Sanofi presently has a consensus rating of “Moderate Buy” and an average target price of $62.67.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.